Live Breaking News & Updates on ரோஜர் பேர்ல்முத்தேர்

Stay updated with breaking news from ரோஜர் பேர்ல்முத்தேர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Eikon Therapeutics closes $148M financing to develop super-resolution microscopy


Eikon Therapeutics closes $148M financing to develop super-resolution microscopy
06 May 2021
California-based firm to integrate advanced optics, machine learning with biochemistry; its target application is drug discovery.
Eikon focuses on live-cell super-resolution microscopy for drug discovery.Eikon Therapeutics, a Hayward, California-based company focused on live-cell super-resolution microscopy and engineering for drug discovery, has this week announced that it has closed a $148 million Series A financing round.
The funding is led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. Eikon also announced the appointment of Roger M. Perlmutter, MD, PhD, as its new Chief Executive Officer. ....

United States , Robert Tjian , Eric Betzig , Luke Lavis , Russ Berman , Roger Perlmutter , Rogerm Perlmutter , Xavier Darzacq , Dan Anderson , University Of California , Merck Research Laboratories , Column Group , Eikon Therapeutics , Foresite Capital , Innovation Endeavors , Chief Executive , Nobel Prize , Cell Biology , Merck Research , Interim President , Senior Vice President , Engineering Russ Berman , ஒன்றுபட்டது மாநிலங்களில் , லூக் லாவிஸ் , ரோஜர் பேர்ல்முத்தேர் , டான் ஆண்டர்சன் ,

Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm


Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm
Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive.
Shares0
 
Eikon Therapeutics, a new biotech startup that uses advanced techniques for visualizing proteins and combines that capability with computational approaches to drug screening , has emerged from stealth with $148 million in funding and a veteran Merck executive at the helm.
The Series A round of funding that Eikon announced Wednesday was led by The Column Group. Roger Perlmutter, the former president of Merck Research Laboratories is the Hayward, California-based startup’s CEO. ....

United States , Roger Perlmutter , Eric Betzig , Xavier Darzacq , University Of California , Merck Research Laboratories , Column Group , Royal Swedish Academy Of Sciences , Royal Swedish Academy , Relay Therapeutics , Foresite Capital , Innovation Endeavors , ஒன்றுபட்டது மாநிலங்களில் , ரோஜர் பேர்ல்முத்தேர் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , மெர்க் ஆராய்ச்சி ஆய்வகங்கள் , நெடுவரிசை குழு , அரச ஸ்விட்ச் கலைக்கழகம் ஆஃப் அறிவியல் , அரச ஸ்விட்ச் கலைக்கழகம் , ரிலே சிகிச்சை , கண்டுபிடிப்பு முயற்சிகள் ,